Sun Pharma announces 5-Year sustained efficacy and safety results for ILUMYA (tildrakizumab-asmn)

▴ Sun Pharma announces 5-Year sustained efficacy and safety results for ILUMYA (tildrakizumab-asmn)
Ilumiya is indicated in patients with moderate-to-severe plaque Psoriasis

Sun Pharmaceutical Industries Limited  today announced that one of its wholly owned subsidiaries presented positive, five-year Phase 3 data for ILUMYA (tildrakizumab-asmn) from the combined reSURFACE 1 and reSURFACE 2 extension studies. Patients with moderate-to-severe plaque psoriasis who continued to receive ILUMYA through five years of continuous treatment maintained consistent and extensive skin clearance with no new safety issues reported

These data were presented for the first time at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress.

“These results are important as we now have five-year data reinforcing our understanding that ILUMYA may provide patients with sustained skin clearance and a well understood safety profile that was comparable to placebo,” said Richard Langley, M.D., FRCPC, professor of medicine and director of research, Department of Medicine, Dalhousie University. “ILUMYA is a valued option for patients in the treatment of moderate-to-severe plaque psoriasis, and these findings are reassuring for physicians and their patients living with this chronic disease.”

In an analysis of the pooled reSURFACE 1 and reSURFACE 2 extension studies, patients received ILUMYA 100 mg or 200 mg through five years of continuous treatment. ILUMYA 100 mg is approved in the U.S., Japan and Australia, and 200 mg is additionally approved under the brand name ILUMETRI™ in Europe. In patients who were treated with ILUMYA 100 mg, clear or almost clear skin 

Tags : #SunPharma #Ilumiya #PlaquePsoriasisTreatment #LatestPharmaNewsNov2

About the Author


Team Medicircle

Related Stories

Loading Please wait...